Letters to the Editor

Dual pyroptotic biomarkers predict erythroid response in lower risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin

Department of Internal Medicine, University of South Florida, Morsani College of Medicine, Tampa, FL, USA; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Service d’Hématologie Biologique, Assistance Publique-Hôpitaux de Paris. Centre-Université de Paris, Hôpital Cochin, Paris
Service d’Hématologie Biologique, Assistance Publique-Hôpitaux de Paris. Centre-Université de Paris, Hôpital Cochin, Paris
Groupe Francophone des Myélodysplasies, Hopital Saint Louis, Paris
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Haematologica Early view Jul 29, 2021 https://doi.org/10.3324/haematol.2021.278855